Inovio’s SynCon™ Universal Influenza DNA Vaccine Technology Recognized with NIH Director’s Transformative Research Award Inovio and University of Pennsylvania Awarded $3.1 Million Grant to Advance ...
Inovio's phase I trial of SynCon flu vaccine generates protective immune respons in elderly patients
Inovio Pharmaceuticals Inc., a company revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases, has reported interim results of a phase I trial that showed ...
It’s an exciting time for cancer treatments, with innovative new drugs and therapies offering hope like never before to patients riddled with the disease that lack options. Consider just this week ...
Inovio Pharmaceuticals demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical ...
Inovio and University of Pennsylvania Awarded $3.1 Million Grant to Advance Universal Influenza DNA Vaccine BLUE BELL, Pa., Sep 30, 2010 (BUSINESS WIRE) -- Inovio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results